Amgen's Strategic Moves Spark Eosinophilic Esophagitis Market Shift
PILLAR DIAGNOSTIC // WEEK 16
“While momentum and bullish clinical projections are powering shares higher, looming competitive pressure from multiple entrants could cap upside that the market hasn’t yet priced, suggesting gains may slow as peers begin eroding MariTide’s market share.”
Proposed action
Maintain core position and avoid chasing rallies; consider modest trims or hedges against potential competitive headwinds.
THE MECHANICS
Tape & flow
Upward price momentum has driven CHD up 8.5% and AMGN up 8.2% over the past 12 weeks.
THE MACHINE
Operational momentum
Confidence in MariTide’s commercial potential in obesity has increased, suggesting stronger future revenue opportunities.
THE MAP
Structure & constraints
US eosinophilic esophagitis market projected to reach USD 647 million by 2025 under strong patent protection through 2040 for Krystexxa, with new entrants such as Tezepelumab, Merited, and Blinatumomab intensifying competition among AstraZeneca, Amgen, Ellodi, and others.
THE MOOD
Consensus & positioning
—
